Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 3:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 536 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: placebo gel Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Male Tolerance Study of Dapivirine Gel Following Multiple Topical Penile Exposures

NCT01277640
View directory record Official record
Conditions
Topical Penile Exposures
Interventions
dapivirine, matched placebo, universal placebo
Drug
Lead sponsor
International Partnership for Microbicides, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
2
States / cities
Birmingham, Alabama • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 8, 2017 · Synced Oct 6, 2026, 3:18 AM EDT
Completed Phase 3 Interventional Results available

A Comparison of a New Drug to Treat Overactive Bladder vs. Placebo

NCT00350636
View directory record Official record
Conditions
Overactive Bladder
Interventions
Oxybutynin topical gel, Placebo topical gel
Drug · Other
Lead sponsor
Watson Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
789 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
63
States / cities
Birmingham, Alabama • Homewood, Alabama • Mobile, Alabama + 60 more
Source: ClinicalTrials.gov public record
Updated May 10, 2010 · Synced Oct 6, 2026, 3:18 AM EDT
Completed Phase 3 Interventional Results available

Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea

NCT01355471
View directory record Official record
Conditions
Rosacea
Interventions
CD07805/47 Gel, Placebo
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
293 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
12
States / cities
Hot Springs, Arkansas • Miami Beach, Florida • Newnan, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 6, 2026, 3:18 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention

NCT04804033
View directory record Official record
Conditions
Migraine
Interventions
BHV-3500 (zavegepant), Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,753 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
116
States / cities
Phoenix, Arizona • Tucson, Arizona • Canoga Park, California + 88 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2025 · Synced Oct 6, 2026, 3:18 AM EDT
Terminated Phase 2Phase 3 Interventional Accepts healthy volunteers

DPI 386 Nasal Gel for the Prevention of Nausea Associated With Motion Sickness

NCT04219982
View directory record Official record
Conditions
Motion Sickness
Interventions
DPI-386 Nasal Gel, DPI-386 Placebo Nasal Gel, Transderm Scop®
Drug
Lead sponsor
Repurposed Therapeutics, Inc.
Industry
Eligibility
18 Years to 59 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 7, 2020 · Synced Oct 6, 2026, 3:18 AM EDT
Terminated Phase 2 Interventional

Efficacy of 851B Gel for Treating High-Risk Cervical Human Papillomavirus Infection in Women.

NCT00117884
View directory record Official record
Conditions
Papillomavirus Infections
Interventions
851B
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
22
States / cities
Colton, California • San Diego, California • Colorado Springs, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2016 · Synced Oct 6, 2026, 3:18 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Influence of Testosterone Administration on Drug-Induced QT Interval Prolongation and Torsades de Pointes

NCT02513940
View directory record Official record
Conditions
Long QT Syndrome
Interventions
Testosterone, Progesterone, Placebo, Ibutilide
Drug
Lead sponsor
Indiana University
Other
Eligibility
65 Years and older · Male only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 6, 2026, 3:18 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Self-administered Intravaginal 2% Lidocaine Gel Prior to Intrauterine Device Insertion in Nulliparous Women

NCT01534520
View directory record Official record
Conditions
Pain
Interventions
Lidocaine, Placebo
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
14 Years to 55 Years · Female only
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 22, 2016 · Synced Oct 6, 2026, 3:18 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Influence of Menthol Gel During Exercise With Heat

NCT05302804
View directory record Official record
Conditions
Acute Exercise, Heat Exposure
Interventions
Menthol Gel, Control Gel
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 45 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 6, 2026, 3:18 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Prevention and Treatment of Nausea Associated With Motion Sickness in Senior Subjects

NCT03988530
View directory record Official record
Conditions
Motion Sickness
Interventions
Scopolamine, Placebo Nasal Gel
Drug · Other
Lead sponsor
Repurposed Therapeutics, Inc.
Industry
Eligibility
55 Years and older
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated May 6, 2023 · Synced Oct 6, 2026, 3:18 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Cannabidiol Effects on Learning and Anxiety

NCT05283382
View directory record Official record
Conditions
Anxiety and Fear
Interventions
Cannabidiol Oral Product, Placebo
Drug · Other
Lead sponsor
University of Connecticut
Other
Eligibility
18 Years to 50 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Storrs, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 6, 2026, 3:18 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Efficacy and Safety of DPI-386 Nasal Gel for the Prevention of Nausea and Vomiting Associated With Motion

NCT05548270
View directory record Official record
Conditions
Motion Sickness
Interventions
DPI-386 Nasal Gel, Placebo
Drug
Lead sponsor
Repurposed Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
503 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Mar 21, 2023 · Synced Oct 6, 2026, 3:18 AM EDT
Not listed Phase 4 Interventional

Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease

NCT00941642
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease
Interventions
Lovaza, placebo control
Drug
Lead sponsor
Huntington Medical Research Institutes
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Jun 10, 2010 · Synced Oct 6, 2026, 3:18 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Botulinum Toxin Type A Topical Gel for Lateral Canthal Lines

NCT02580370
View directory record Official record
Conditions
Skin Aging
Interventions
Botulinum toxin type A, Placebo comparator
Biological
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Sep 9, 2016 · Synced Oct 6, 2026, 3:18 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Phase III Study of a Topical Gel Formulation for Treatment and Prevention of Raynaud's Phenomenon

NCT00419419
View directory record Official record
Conditions
Raynaud's Disease, Scleroderma, Autoimmune Diseases
Interventions
Topical AmphiMatrix with nitroglycerin (MQX-503)
Drug
Lead sponsor
MediQuest Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2006
U.S. locations
6
States / cities
Stanford, California • Farmington, Connecticut • Washington D.C., District of Columbia + 3 more
Source: ClinicalTrials.gov public record
Updated May 30, 2007 · Synced Oct 6, 2026, 3:18 AM EDT
Terminated Phase 1 Interventional

Effect of Increasing Testosterone on Insulin Sensitivity in Men With the Metabolic Syndrome

NCT00438321
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
Zoladex, Testosterone gel, Anastrozole Pill, Placebo
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
50 Years to 75 Years · Male only
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Oct 6, 2026, 3:18 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Safety and the Efficacy of EscharEx (EX-02 Formulation) in Debridement of Venous Leg Ulcers

NCT03588130
View directory record Official record
Conditions
Venous Leg Ulcer
Interventions
EscharEx (5% EX-02 formulation), Gel Vehicle, Non-surgical standard of care (NSSOC)
Drug
Lead sponsor
MediWound Ltd
Industry
Eligibility
18 Years to 90 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
21
States / cities
Carlsbad, California • Fresno, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2022 · Synced Oct 6, 2026, 3:18 AM EDT
Terminated Phase 2 Interventional Results available

ACTH in Progressive Forms of MS

NCT01950234
View directory record Official record
Conditions
Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
Interventions
ACTH, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
3
States / cities
Minneapolis, Minnesota • Fargo, North Dakota • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 11, 2025 · Synced Oct 6, 2026, 3:18 AM EDT
Terminated Phase 2 Interventional Results available

Vitamin D and n-3 Polyunsaturated Fatty Acids (PUFAs) to Prevent Chronic Pain Following Major Thermal Burn Injury

NCT03313076
View directory record Official record
Conditions
Chronic Pain Following Thermal Burn Injury
Interventions
Omega-3 fatty acids (fish oil), Vitamin D3 (cholecalciferol), Vitamin D3 (cholecalciferol) placebo, Omega-3 fatty acid placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 6, 2026, 3:18 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Wayfinding Intervention in High-Fidelity Long-Term Memory

NCT04253587
View directory record Official record
Conditions
Long-Term Memory Decline, Mild Cognitive Impairment
Interventions
LabyrinthVR, Placebo Games, Coherence, Tablet
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
62 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 27, 2023 · Synced Oct 6, 2026, 3:18 AM EDT
Completed Phase 2 Interventional Results available

Antibacterial Mouthwash for Pharyngeal Gonorrhea Prevention

NCT04966507
View directory record Official record
Conditions
Gonorrhea
Interventions
Listerine Antiseptic Mouthwash Product, Biotene Mouthwash
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 45 Years · Male only
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 6, 2026, 3:18 AM EDT
Terminated Phase 2Phase 3 Interventional

Efficacy Study of Adrenocorticotropin Hormone to Treat Multiple Sclerosis (MS) Relapses After Sub-responding to an Initial 3 Day Course of Intravenous (IV) Methylprednisolone

NCT00947895
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Methylprednisolone, ACTH, IV placebo, IM placebo
Drug · Other
Lead sponsor
Neurologique Foundation, Inc.
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Ponte Vedra, Florida
Source: ClinicalTrials.gov public record
Updated Mar 22, 2016 · Synced Oct 6, 2026, 3:18 AM EDT
Completed Phase 1Phase 2 Interventional

Safety, Pharmacokinetics and Efficacy of FMX114 Versus Vehicle in Adults With Atopic Dermatitis

NCT04927572
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
FMX114, Vehicle
Drug · Other
Lead sponsor
Vyne Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
4
States / cities
Miami, Florida • Miramar, Florida • Sugarloaf, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 31, 2022 · Synced Oct 6, 2026, 3:18 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Comparison of Topical 0.15% Gancyclovir Gel Versus 0.3% Hypromellose Gel for the Treatment of Herpes Zoster Keratitis

NCT02382588
View directory record Official record
Conditions
Herpes Zoster Keratitis
Interventions
gancyclovir gel, Hypromellose gel
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 95 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 8, 2021 · Synced Oct 6, 2026, 3:18 AM EDT